GAO evaluation of device reuse
This article was originally published in The Gray Sheet
Senate Health, Education, Labor and Pensions Committee in July 26 letter to the General Accounting Office asks the investigative body to evaluate the appropriateness of FDA's current reprocessing policy, which "does not distinguish between different classes and types of medical devices (i.e., can some single-use devices be safely reprocessed but not others)." The committee members also ask GAO to analyze additional questions regarding reprocessing, such as the economic impact of reusing disposable products and the cost of requiring FDA to assure the safety and efficacy of reprocessed single-use devices for their intended use (1"The Gray Sheet" July 26, p. 7)
You may also be interested in...
The Senate Health, Education, Labor and Pensions Committee will ask the General Accounting Office to undertake a comprehensive evaluation of the practice of reprocessing devices, according to committee staffers.
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.